CDK7 and breast cancer: A study investigated that the CDK7 inhibitor THZ1 reported that TNBC cell lines exhibited greater sensitivity to CDK7 inhibition than ER‐positive cells, as seen by potent inhibition of cell proliferation; however, phospho‐PolII status was equally affected in both BC subtypes.134